Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with severe eczema: dupilumab shows promise in japanese trial

NCT ID NCT04678882

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug dupilumab (given as a shot) plus steroid creams in 62 Japanese children aged 6 months to 18 years with moderate-to-severe eczema that wasn't controlled by other treatments. The goal was to see if dupilumab could improve skin symptoms and itching over 16 weeks. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dupilumab (a biologic drug given as a shot under the skin)
What this could lead to
If it works, this could offer a new treatment option for Japanese children with hard-to-control eczema, reducing itch and skin inflammation.
What could go wrong
This is a completed Phase 3 trial with only 62 participants, all Japanese. Results may not apply to other groups, and dupilumab can cause side effects like injection reactions or eye problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

  • Investigational Site Number : 3920001

    Hiroshima, Hiroshima, 734-8551, Japan

  • Investigational Site Number : 3920003

    Sagamihara-shi, Kanagawa, 252-0392, Japan

  • Investigational Site Number : 3920006

    Tsu, Mie-ken, 514-0125, Japan

  • Investigational Site Number : 3920007

    Kobe, Hyōgo, 658-0082, Japan

  • Investigational Site Number : 3920008

    Kobe, Hyōgo, 653-0836, Japan

  • Investigational Site Number : 3920009

    Sapporo, Hokkaido, 060-0807, Japan

  • Investigational Site Number : 3920010

    Yokohama, Kanagawa, 225-0015, Japan

  • Investigational Site Number : 3920011

    Nagoya, Aichi-ken, 457-8510, Japan

  • Investigational Site Number : 3920012

    Koto-ku, Tokyo, 136-0074, Japan

  • Investigational Site Number : 3920013

    Sapporo, Hokkaido, 004-0063, Japan

  • Investigational Site Number : 3920014

    Toyoake-shi, Aichi-ken, 470-1192, Japan

  • Investigational Site Number : 3920015

    Fukutsu-shi, Fukuoka, 811-3217, Japan

  • Investigational Site Number : 3920016

    Kumagaya-shi, Saitama, 360-0018, Japan

  • Investigational Site Number : 3920017

    Yokohama, Kanagawa, 221-0825, Japan

  • Investigational Site Number : 3920019

    Toyonaka-shi, Osaka, 560-0085, Japan

  • Investigational Site Number : 3920020

    Sakai-shi, Osaka, 593-8324, Japan

  • Investigational Site Number : 3920021

    Habikino-shi, 583-8588, Japan

  • Investigational Site Number : 3920022

    Toshima-ku, Tokyo, 170-0002, Japan

  • Investigational Site Number : 3920023

    Chuo-ku, Tokyo, 104-0031, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.